Günter Eisele1, Ulrich Roelcke2, Katrin Conen3, Fabienne Huber1, Tobias Weiss1, Silvia Hofer4, Oliver Heese5, Manfred Westphal6, Caroline Hertler1, Patrick Roth1, Michael Weller1. 1. Department of Neurology, University Hospital Zurich and University of Zurich, Switzerland. 2. Department of Neurology and Brain Tumor Center, Aarau, Switzerland. 3. Department of Oncology, University Hospital Basel, Switzerland and Department of Family Medicine McMaster University, Hamilton, Canada. 4. Department of Oncology, University Hospital Zurich, Switzerland. 5. Department of Neurosurgery, Helios Kliniken, Schwerin, Germany. 6. Department of Neurosurgery, University Hospital Eppendorf, Hamburg, Germany.
Abstract
BACKGROUND: During the course of disease, most glioma patients learn that there is no cure for their tumor. It is therefore not uncommon for patients or caregivers to seek complementary and alternative medicine (CAM) treatments. Patterns of CAM use vary across the globe, but little is known about the type of, and motivation for, CAM use in most countries. METHODS: Here we conducted a cross-sectional survey of CAM use in patients harboring gliomas of World Health Organization (WHO) grades II to IV at 3 specialized neuro-oncology centers in Switzerland. RESULTS: Of 208 patients who returned the survey, approximately half reported having used or using CAM. CAM use was associated with younger age. Patients suffering from WHO grade II gliomas were less likely to indicate CAM use. The leading motivation for CAM use was to contribute actively to the treatment of the disease. CAM use was commonly not counseled or supervised by a health care professional. Cost and issues of reimbursement were not an important factor in the decision against or for CAM use. CONCLUSIONS: Physicians caring for glioma patients should be aware of and explore CAM use to better understand patients' attitudes toward their disease, to provide counseling, and to identify potential interactions of CAM with standard treatments for gliomas.
BACKGROUND: During the course of disease, most glioma patients learn that there is no cure for their tumor. It is therefore not uncommon for patients or caregivers to seek complementary and alternative medicine (CAM) treatments. Patterns of CAM use vary across the globe, but little is known about the type of, and motivation for, CAM use in most countries. METHODS: Here we conducted a cross-sectional survey of CAM use in patients harboring gliomas of World Health Organization (WHO) grades II to IV at 3 specialized neuro-oncology centers in Switzerland. RESULTS: Of 208 patients who returned the survey, approximately half reported having used or using CAM. CAM use was associated with younger age. Patients suffering from WHO grade II gliomas were less likely to indicate CAM use. The leading motivation for CAM use was to contribute actively to the treatment of the disease. CAM use was commonly not counseled or supervised by a health care professional. Cost and issues of reimbursement were not an important factor in the decision against or for CAM use. CONCLUSIONS: Physicians caring for glioma patients should be aware of and explore CAM use to better understand patients' attitudes toward their disease, to provide counseling, and to identify potential interactions of CAM with standard treatments for gliomas.
Entities:
Keywords:
Switzerland; alternative medicine; complementary medicine; glioma
Authors: Terri Armstrong; Marlene Z Cohen; Kenneth R Hess; Rochelle Manning; Eva Lu T Lee; Geline Tamayo; Karen Baumgartner; Sur J Min; Alfred Yung; Mark Gilbert Journal: J Pain Symptom Manage Date: 2006-08 Impact factor: 3.612
Authors: Robert B Saper; Russell S Phillips; Anusha Sehgal; Nadia Khouri; Roger B Davis; Janet Paquin; Venkatesh Thuppil; Stefanos N Kales Journal: JAMA Date: 2008-08-27 Impact factor: 56.272
Authors: Amanda Munoz-Casabella; Dietlind L Wahner-Roedler; Ivana T Croghan; Tanya M Petterson; Debbie L Fuehrer; Brent A Bauer Journal: Glob Adv Health Med Date: 2022-03-25
Authors: Dorothee Gramatzki; James Louis Rogers; Marian Christoph Neidert; Caroline Hertler; Emilie Le Rhun; Patrick Roth; Michael Weller Journal: Neurooncol Pract Date: 2020-04-25